Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 16/20 | 0.38 |
| ▸ | PLK2 | Q9NYY3 | 16/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | PLK3 | Q9H4B4 | 14/20 | 0.36 |
| ▸ | TAF1 | P21675 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18475419 | 1.00 | PLK1 (0.38) | PLK1PLK2BRD4PLK3TAF1 | |
| SCHEMBL14193656 | 0.80 | PLK1 (0.37) | PLK1PLK2BRD4PLK3TAF1 | |
| SCHEMBL7750944 | 0.79 | PLK1 (0.37) | PLK1PLK2BRD4PLK3TAF1 | |
| SCHEMBL16984420 | 0.77 | PLK1 (0.37) | PLK1PLK2BRD4PLK3TAF1 | |
| SCHEMBL10144547 | 0.70 | PLK1 (0.39) | PLK1PLK2BRD4PLK3 | |
| SCHEMBL16984508 | 0.70 | OPRM1 (0.32) | PLK1PLK2PLK3ALDH1A1CYP2C9 | |
| SCHEMBL6840385 | 0.69 | PLK1 (0.34) | PLK1PLK2BRD4PLK3TAF1 | |
| SCHEMBL11957666 | 0.69 | PLK1 (0.46) | PLK1PLK2BRD4PLK3 | |
| SCHEMBL10093296 | 0.69 | PLK1 (0.30) | PLK1PLK2PLK3 | |
| SCHEMBL16984507 | 0.68 | PLK1 (0.31) | PLK1PLK2BRD4PLK3TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2017024318-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |